SENTINEL LYMPH NODE BIOPSY FOR MELANOMA AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND SOCIETY OF SURGICAL ONCOLOGY JOINT CLINICAL PRACTICE GUIDELINE

Size: px
Start display at page:

Download "SENTINEL LYMPH NODE BIOPSY FOR MELANOMA AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND SOCIETY OF SURGICAL ONCOLOGY JOINT CLINICAL PRACTICE GUIDELINE"

Transcription

1 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND SOCIETY OF SURGICAL ONCOLOGY JOINT CLINICAL PRACTICE GUIDELINE

2 Introduction Population: patients with newly diagnosed melanoma Metastases to regional lymph nodes most important prognostic factor in early-stage melanoma Occur in 20% of patients with intermediate-thickness tumors (1-4 mm Breslow thickness) Sentinel lymph node (SLN) biopsy is accurate in staging regional nodes and has low morbidity Previous studies Multicenter Selective Lymphadenectomy Trial I (MSLT I) and Sunbelt Melanoma Trial SLN biopsy vs. nodal observation no difference in melanomaspecific survival (MSLT I) Positive SLN followed by completion lymph node dissection (CLND) benefit in melanoma-specific survival, prolonged disease-free survival, decreased risk of recurrence

3 Abbreviations SLN: sentinel lymph node CLND: completion lymph node dissection PSM: proportion of patients successfully mapped PVP: predictive value positive PVN: predictive value negative PTPN: post-test probability negative (1-PVN) FNR: false-negative rate (false negative/[true positive + false negative])

4 Guideline Methodology: Systematic Review ASCO and Society of Surgical Oncology (SSO) convened an Expert Panel to review relevant medical literature Systematic review Date parameters: January 1990-August 2011 Databases searched: MEDLINE EMBASE ASCO and SSO Annual Meeting proceedings searched Meta-analysis completed (Valsecchi et al, JCO, 2011)

5 Limitations of the literature Only one randomized clinical trial that addresses whether patients with melanoma managed using SLN biopsy have better clinical outcomes than those managed any other way Multicenter Selective Lymphadenectomy Trial I (MSLT-I) Systematic review, by necessity, included observational studies Cohort studies (SLN biopsy with or without CLND) Significant variability across studies (e.g., in techniques used)

6 Clinical Questions 1. What are the indications for sentinel lymph node biopsy? 2. What is the role of completion lymph node dissection?

7 Recommendation 1 What are the indications for sentinel lymph node biopsy? Intermediate-thickness melanomas. SLN biopsy is recommended to patients with intermediate-thickness cutaneous melanomas (1 to 4 mm Breslow thickness) of any anatomic site. Routine use of SLN biopsy in this population provides accurate staging, with high estimates for PSM, and acceptable estimates for FNR, PTPN, and PVP. (continued on next slide)

8 Recommendation 1, cont d Thick melanomas. While there are few studies focusing specifically on patients with thick melanomas (T4; > 4 mm Breslow thickness), the use of SLN biopsy in this population may be recommended for staging purposes and to facilitate regional disease control. Thin melanoma. There is insufficient evidence to support routine SLN biopsy for patients with thin melanoma (T1; < 1 mm Breslow thickness), although it may be considered in selected cases with high risk features, when the benefits of pathologic staging may outweigh the potential risks of the procedure. Such risk factors may include ulceration or mitotic rate 1/mm 2, especially in the subgroup of patients with Breslow thickness 0.75 mm to 0.99 mm.

9 Recommendation 2 What is the role of completion lymph node dissection? Recommendation CLND is recommended for all patients with a positive SLN biopsy. CLND achieves regional disease control, although whether or not CLND following a positive SLN biopsy improves survival is the subject of the ongoing Multicenter Selective Lymphadenectomy Trial II (MSLT II).

10 PATIENT AND CLINICIAN COMMUNICATION Patient counseling is essential for informed decision-making Key question: What additional information necessary to guide a choice of treatment will SLN biopsy likely provide? Conduct an open dialogue that: Discusses scientific evidence (in lay terms) Weighs individual risks with potential harms and benefits Considers patient values and preferences Consider using ASCO treatment plan template on asco.org. { urement+%26+improvement/chemotherapy+treatment+plan+and+summary/cancer +Treatment+Plan+and+Summary+Resources}

11 Future Directions Determining precise criteria for patient selection for SLN biopsy. Determining whether early identification of metastases in the SLN improves survival or is just lead time bias. Identifying criteria for individualized risks that best inform appropriate risk stratification for patients at high risk for relapse, and those for whom CLND and/or adjuvant therapy are suitable. Establishing the role of prognostic markers from primary melanoma and SLN for appropriate risk stratification. Development of prediction-based models to aid in individualized decision-making.

12 The Bottom Line Intervention SLN biopsy for patients with newly diagnosed melanoma Target Audience Surgical Oncologists, Medical Oncologists, Dermatologists, Primary Care Physicians, Pathologists, Nuclear Medicine Specialists Key Recommendations Intermediate-thickness melanomas: SLN biopsy is recommended to patients with cutaneous melanomas with 1 to 4 mm Breslow thickness of any anatomic site. Thick melanomas: SLN biopsy may be recommended for staging purposes and to facilitate regional disease control for patients with melanomas that are T4 or > 4 mm Breslow thickness. Thin melanomas: There is insufficient evidence to support SLN biopsy for patients with melanomas that are T1 or < 1 mm Breslow thickness, although it may be considered in selected high-risk cases. Completion lymph node dissection is recommended for all patients with a positive SLN biopsy. Methods An Expert Panel was convened to develop guideline recommendations based on their review of evidence from a systematic review of the medical literature.

13 Guideline Methodology: Panel Members Panel Members Affiliation/Institution Sandra L. Wong, MD, Co-Chair University of Michigan Gary H. Lyman, MD, MPH, Co-Chair Sanjiv S. Agarwala, MD Timothy J. Akhurst, MD Charles M. Balch, MD Alistair Cochran, MD Janice N. Cormier, MD, MPH Mark Gorman Theodore Y. Kim, DO, MS Duke University St. Luke s Cancer Center Peter MacCallum Cancer Institute University of Texas Southwestern UCLA Center for Health Services University of Texas MD Anderson Cancer Center National Coalition for Cancer Survivorship Skagit Valley Regional Cancer Center

14 Guideline Methodology: Panel Members, cont d Panel Members Kelly McMasters, MD, PhD Affiliation/Institution University of Louisville R. Dirk Noyes, MD Huntsman Cancer Institute Lynn Mara Schuchter, MD Matias E. Valsecchi, MD Donald L. Weaver, MD University of Pennsylvania Thomas Jefferson University University of Vermont College of Medicine

15 Additional ASCO Resources The Executive Summary of the full Guideline includes the clinical questions, recommendations, a brief summary of the literature, and discussions. (JCO and the Annals of Surgical Oncology jointly published this.) The full Guideline (which includes a comprehensive discussion of the literature, a description of the methodology, and a complete reference list), along with a Data Supplement, an Appendix, and clinical tools and resources, can be found at or online at the SSO website Meta-analysis and systematic review was published (Valsecchi ME, Silbermins D, de Rosa N, et al: Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol 29: , 2011) A patient guide is available at

16 ASCO Guidelines This resource is a practice tool for physicians based on an ASCO practice guideline. The practice guideline and this presentation are not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients and may not reflect the most recent evidence. This presentation does not recommend any particular product or course of medical treatment. Use of the practice guideline and this resource is voluntary. The full practice guideline and additional information are available at Copyright 2012 by American Society of Clinical Oncology. All rights reserved.

Guideline Development The American Society of Clinical Oncology

Guideline Development The American Society of Clinical Oncology Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary

More information

2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma

2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma 2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma Focus on stage III and IV melanoma In partnership with the Society of Surgical Oncology (SSO) 12-14 November 2015 ATHENS (GR)

More information

Prostate Cancer. Treatments as unique as you are

Prostate Cancer. Treatments as unique as you are Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential

More information

How To Compare The Effects Of A Hysterectomy And A Hysterectomy

How To Compare The Effects Of A Hysterectomy And A Hysterectomy A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer

More information

Survivorship Care Plans Guides for Living After Cancer Treatment

Survivorship Care Plans Guides for Living After Cancer Treatment Survivorship Care Plans Guides for Living After Cancer Treatment Institute of Medicine Report 2005 Recommendations for meeting needs of cancer survivors Implement survivorship care plan Build bridges

More information

Individual Prediction

Individual Prediction Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department

More information

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

www.asco.org/guidelines/ 2014 American Society of Clinical Oncology. All rights reserved.

www.asco.org/guidelines/ 2014 American Society of Clinical Oncology. All rights reserved. Screening, Assessment and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation Introduction This guideline summarizes the

More information

RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?

RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What? RESEARCH EDUCATE ADVOCATE Just Diagnosed with Melanoma Now What? INTRODUCTION If you are reading this, you have undergone a biopsy (either of a skin lesion or a lymph node) or have had other tests in which

More information

ADJUVANT RADIATION FOR MALIGNANT MELANOMA

ADJUVANT RADIATION FOR MALIGNANT MELANOMA ADJUVANT RADIATION FOR MALIGNANT MELANOMA Effective Date: February 2014 The recommendations contained in this guideline are a consensus of the Alberta Cutaneous Tumour Team and are a synthesis of currently

More information

Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma

Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma Ann Surg Oncol (2014) 21:3117 3123 DOI 10.1245/s10434-014-3758-7 ORIGINAL ARTICLE MELANOMAS Observation After a Positive Sentinel Lymph Node Biopsy in Patients with Melanoma Zubin M. Bamboat, MD 1, Ioannis

More information

Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation

Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George

More information

Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline

Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:

More information

Melanoma: assessment and management of melanoma

Melanoma: assessment and management of melanoma Melanoma: assessment and management of melanoma NICE guideline Draft for consultation, January 2015 If you wish to comment on this version of the guideline, please be aware that all the supporting information

More information

In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer

In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer Prostate cancer is the second most common cancer in men worldwide, accounting for 15% of all new cancer cases. 1 Great strides have

More information

INTERDISCIPLINARY CONFERENCE. Florence/Firenze, Italy Nov 27-29, 2012 Centro Congressi al Duomo, Firenze BREAST SEMINAR SERIES

INTERDISCIPLINARY CONFERENCE. Florence/Firenze, Italy Nov 27-29, 2012 Centro Congressi al Duomo, Firenze BREAST SEMINAR SERIES Since breast cancer is not a systemic disease from inception, when the imagers find in situ and 1-14 mm invasive breast cancer, it is the surgeon, specialized in the treatment of breast diseases, who should

More information

Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases

Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases Clinical Practice Guideline www.asco.org/guidelines/her2brainmets American Society of Clinical

More information

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History

More information

Breast Health Program

Breast Health Program Breast Health Program Working together, for your health. Breast Health Program The Breast Health Program at The University of Arizona Cancer Center offers patients a personalized approach to breast cancer,

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer

Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer CLINICAL PRACTICE GUIDELINE www.asco.org/guidelines/treather2pos American Society of Clinical Oncology. All rights reserved. Introduction

More information

Big Data and Oncology Care Quality Improvement in the United States

Big Data and Oncology Care Quality Improvement in the United States Big Data and Oncology Care Quality Improvement in the United States Peter P. Yu, MD, FACP, FASCO President, American Society of Clinical Oncology Director of Cancer Research, Palo Alto Medical Foundation

More information

Breast. Patient information. cancer clinical pathway

Breast. Patient information. cancer clinical pathway Breast Patient information cancer clinical pathway This leaflet was written to properly inform people following breast cancer treatment plan. It doesn t replace the dialogue with healthcare staff; it rather

More information

California HealthCare Foundation Education materials for patients with advanced cancer

California HealthCare Foundation Education materials for patients with advanced cancer California HealthCare Foundation Education materials for patients with advanced cancer The California HealthCare Foundation (CHCF) commissioned research to explore options around the development of patient

More information

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof

More information

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone

More information

PSA Screening and the USPSTF Understanding the Controversy

PSA Screening and the USPSTF Understanding the Controversy PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based

More information

The iq&a interactive Medical Intelligence Zone BRCA Gene Testing

The iq&a interactive Medical Intelligence Zone BRCA Gene Testing The iq&a interactive Medical Intelligence Zone BRCA Gene Testing for Breast Cancer Focus on Guideline-Directed BRCA-1 and BRCA-2 Diagnostic Testing and Evidence-Based Management of Breast Cancer A Year

More information

Critical Appraisal of Article on Therapy

Critical Appraisal of Article on Therapy Critical Appraisal of Article on Therapy What question did the study ask? Guide Are the results Valid 1. Was the assignment of patients to treatments randomized? And was the randomization list concealed?

More information

Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care

Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care Cancer Treatment Planning: A Means to Deliver Quality, Patient-Centered Care Patricia A. Ganz, M.D. Jonsson Comprehensive Cancer Center UCLA Schools of Medicine & Public Health Overview of Presentation

More information

How to treat early gastric cancer. Surgery

How to treat early gastric cancer. Surgery How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies

More information

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a

More information

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

2014 Report of Cancer Program Activities for 2013

2014 Report of Cancer Program Activities for 2013 2014 Report of Cancer Program Activities for 2013 The University of Vermont Health Network-Central Vermont Medical Center (UVMHN-CVMC) Cancer Committee is pleased to present our Cancer Program Annual Report

More information

Breast Cancer Recurrence Assay (MammaPrint )

Breast Cancer Recurrence Assay (MammaPrint ) Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline

The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline Introduction ASCO convened an Update Committee to review and update the 2002 recommendations for the role of bisphosphonates

More information

The Center for Prostate Cancer. Personalized Treatment. Clinical Excellence.

The Center for Prostate Cancer. Personalized Treatment. Clinical Excellence. The Center for Prostate Cancer Personalized Treatment. Clinical Excellence. The Center for Prostate Cancer Leaders in Prostate Cancer Treatment and Research The Center for Prostate Cancer at the North

More information

Treating Melanoma S kin Cancer A Quick Guide

Treating Melanoma S kin Cancer A Quick Guide Treating Melanoma Skin Cancer A Quick Guide Contents This is a brief summary of the information on Treating melanoma skin cancer from our website. You will find more detailed information on the website.

More information

The lymphatic system consists of a network of vessels

The lymphatic system consists of a network of vessels IMAGING Whole-Body Lymphoscintigraphy Using Transmission Scans Martha Vallejo Mar, BBA, CNMT; Sonia Gee-Johnson, BS, CNMT; E. Edmund Kim, MD; and Donald A. Podoloff, MD Department of Nuclear Medicine,

More information

Access to hormone receptor testing and other basic diagnostic pathology services in Colombia

Access to hormone receptor testing and other basic diagnostic pathology services in Colombia Access to hormone receptor testing and other basic diagnostic pathology services in Colombia Dr Fernando Perry Clínica de seno y tejidos blandos Instituto Nacional de Cancerología de Colombia Breast cancer

More information

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3

More information

The PLCO Trial Not a comparison of Screening vs no Screening

The PLCO Trial Not a comparison of Screening vs no Screening PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical

More information

PCORI Methodology Standards: Academic Curriculum. 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved.

PCORI Methodology Standards: Academic Curriculum. 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved. PCORI Methodology Standards: Academic Curriculum 2016 Patient-Centered Outcomes Research Institute. All Rights Reserved. Module 9: Putting it All Together: Appraising a Systematic Review Category 11: Systematic

More information

Melanoma: National Collaborating Centre for Cancer. assessment and management. NICE guideline NG14. July 2015. Melanoma.

Melanoma: National Collaborating Centre for Cancer. assessment and management. NICE guideline NG14. July 2015. Melanoma. National Collaborating Centre for Cancer Melanoma Melanoma: assessment and management NICE guideline NG14 Full guideline July 2015 Final Commissioned by the National Institute for Health and Care Excellence

More information

A Checklist for Patients with Breast Cancer

A Checklist for Patients with Breast Cancer A Checklist for Patients with Breast Cancer Questions to Ask the Doctor 1 and Quick Help Resources 1 Adapted from: American Cancer Society. Detailed Guide: Breast Cancer - What Should You Ask Your Doctor

More information

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016

INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 INTERPRETING CLINICAL DATA: Highlights From ASCO 2016 SATURDAY, JUNE 25, 2016 Detroit Marriott - Troy, MI AGENDA Time Topic Speaker 7:30 am Registration and Continental Breakfast 8:00 am Opening Remarks/Welcome

More information

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in

More information

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.

More information

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women

More information

New Treatment Advances for Breast Cancer

New Treatment Advances for Breast Cancer New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center

More information

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015 Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer

More information

The evolution of rectal cancer therapy. Objectives

The evolution of rectal cancer therapy. Objectives The evolution of rectal cancer therapy Hagen Kennecke MD MHA FRCPC Western Canada Consensus Conference September 5, 2014 Objectives Identify standard therapy: stage II/III rectal cancer Update recent adjuvant

More information

Breast Cancer Care & Research

Breast Cancer Care & Research Breast Cancer Care & Research Professor John FR Robertson University of Nottingham Nottingham City Hospital Breast Cancer (BC) 15,000 BC deaths in the UK each year 20% female cancer deaths 5% all female

More information

Cancer Care Delivered Locally by Physicians You Know and Trust

Cancer Care Delivered Locally by Physicians You Know and Trust West Florida Physician Office Building Johnson Ave. University Pkwy. Olive Road N. Davis Hwy. For more information on West Florida Cancer Center: 850-494-5404 2130 East Johnson Avenue Pensacola, Florida

More information

Breast Cancer Educational Program. June 5-6, 2015

Breast Cancer Educational Program. June 5-6, 2015 Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:

More information

STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services

STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: Petitioner, v Blue Care Network of Michigan, Respondent. File

More information

Surgical guidelines for the management of breast cancer

Surgical guidelines for the management of breast cancer Available online at www.sciencedirect.com EJSO xx (2009) S1eS22 www.ejso.com Guidelines Surgical guidelines for the management of breast cancer Contents Association of Breast Surgery at BASO 2009 Introduction...

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Does my patient need more therapy after prostate cancer surgery?

Does my patient need more therapy after prostate cancer surgery? Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier

More information

E UROPEAN CURRICULUM VITAE FORMAT

E UROPEAN CURRICULUM VITAE FORMAT E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Address VALENTINA GUARNERI University of Padova Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche Istituto Oncologico Veneto

More information

Types of Studies. Systematic Reviews and Meta-Analyses

Types of Studies. Systematic Reviews and Meta-Analyses Types of Studies Systematic Reviews and Meta-Analyses Important medical questions are typically studied more than once, often by different research teams in different locations. A systematic review is

More information

Ask Us About Clinical Trials

Ask Us About Clinical Trials Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing

More information

Contents. Updated July 2011

Contents. Updated July 2011 - Updated July 2011 Guideline Authors: Todd S. Crocenzi, M.D.; Mark Whiteford, M.D.; Matthew Solhjem, M.D.; Carlo Bifulco, M.D.; Melissa Li, M.D.; Christopher Cai, M.D.; and James Durham, M.D. Contents

More information

The Role of Laparoscopy in Endometrial Cancer

The Role of Laparoscopy in Endometrial Cancer The Role of Laparoscopy in Endometrial Cancer Prof. Dr. Tugan BEŞE İstanbul University, Cerrahpaşa Medical Faculty Gynecologic Oncology Department Surgical staging in Endometrial Cancer Laparoscopic surgery

More information

Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies

Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Richard Wender, MD Session code: www.worldcancercongress.org A Five Step Framework to Guide Screening

More information

Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD

Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence. Cord Sturgeon, MD Thyroid Cancer: Resection, Dissection, Surveillance and Recurrence Cord Sturgeon, MD Associate Professor of Surgery Northwestern University Feinberg School of Medicine Director of Endocrine Surgery Chicago,

More information

The 4Kscore blood test for risk of aggressive prostate cancer

The 4Kscore blood test for risk of aggressive prostate cancer The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6

More information

ORIGINAL ARTICLE THORACIC ONCOLOGY

ORIGINAL ARTICLE THORACIC ONCOLOGY Ann Surg Oncol (2013) 20:1934 1940 DOI 10.1245/s10434-012-2800-x ORIGINAL ARTICLE THORACIC ONCOLOGY Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive

More information

When the diagnosis is cancer, many people

When the diagnosis is cancer, many people Hard decisions about cancer 5 tests and treatments to question When the diagnosis is cancer, many people understandably want to pull out all the stops to treat it. But some tests, treatments, and procedures

More information

MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH 03104 (603) 695-2850

MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH 03104 (603) 695-2850 LEBANON Lung Cancer Screening Program One Medical Center Drive Lebanon, NH 03756 (603) 650-4400 (866) 966-1601 Toll-free cancer.dartmouth.edu/lungscreening MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Melanoma The Skin Understanding Cancer

Melanoma The Skin Understanding Cancer Melanoma A form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or

More information

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript

NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript NIH Public Access Author Manuscript Published in final edited form as: Ann Surg Oncol. 2012 August ; 19(8): 2547 2555. doi:10.1245/s10434-012-2398-z. Metastasectomy for distant metastatic melanoma: Analysis

More information

Jurisdiction Virginia

Jurisdiction Virginia PROPOSED/DRAFT Local Coverage Determination (LCD): MolDX: Prolaris Prostate Cancer Genomic Assay (DL35629) Please note: This is a Proposed/Draft policy. Proposed/Draft LCDs are works in progress that are

More information

PAPER. Surgical Management of the Groin Lymph Nodes in Melanoma in the Era of Sentinel Lymph Node Dissection

PAPER. Surgical Management of the Groin Lymph Nodes in Melanoma in the Era of Sentinel Lymph Node Dissection PAPER Surgical Management of the Groin Lymph Nodes in Melanoma in the Era of Sentinel Lymph Node Dissection Richard Essner, MD; Randall Scheri, MD; Maihgan Kavanagh, MD; Hitoe Torisu-Itakura, MD, PhD;

More information

CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV

CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV Meta-analisis LACE: adyuvancia vs no adyuvancia Pignon JP, et al.

More information

7 th Edition Staging. AJCC 7 th Edition Staging. Disease Site Webinar. Melanoma of Skin. Overview. This webinar is sponsored by

7 th Edition Staging. AJCC 7 th Edition Staging. Disease Site Webinar. Melanoma of Skin. Overview. This webinar is sponsored by AJCC 7 th Edition Staging Melanoma of Skin Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310 from The Centers

More information

Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS

Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum

More information

Hereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center

Hereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center Hereditary Multifocal Breast Cancer Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center CASE STUDY 30 year old Ashkenazi Jewish woman Nulliparous Felt

More information

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced

More information

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

More information

Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT. Five-year report

Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT. Five-year report Breast Cancer & Treatment in ACT and Surrounding Regions QUALITY ASSURANCE PROJECT Five-year report Community Health Pathology Southern Area Health Service ACT Health General Practitioners Nurses Social

More information

Basics and limitations of adjuvant online an internet based decision tool

Basics and limitations of adjuvant online an internet based decision tool Basics and limitations of adjuvant online an internet based decision tool J. Huober SAKK, Bern 31.10.2013 Univ.-Frauenklinik Ulm Integratives Tumorzentrum des Universitätsklinikums und der Medizinischen

More information

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.

Chemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen. Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell

More information

ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival

ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival It is logical that the Cancer Program Committee choose to review the Lung Site, as Lung is the second

More information

Endometrial Cancer Treatment

Endometrial Cancer Treatment Endometrial Cancer Treatment January 2006 By Shelly Smits, RHIT, CCS, CTR mary by Ian Thompson, MD Data Source: Cancer registry information on uterine cancer diagnosed 1/1/2000 to 12/31/2004. Reason for

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

Bristol Hospital Cancer Care Center 2015 Annual Report

Bristol Hospital Cancer Care Center 2015 Annual Report Bristol Hospital Cancer Care Center 2015 Annual Report 2015 Annual Report Cancer Care Center At every point along the path, our team is there, keeping the focus on the most important team member - the

More information

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James

More information

Guide to Understanding Breast Cancer

Guide to Understanding Breast Cancer An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients

More information

The German Programme for Guidelines in Oncology

The German Programme for Guidelines in Oncology The German Programme for Guidelines in Oncology Ina Kopp Markus Follmann International Symposium on Evidence-based Cochrane Reviews in Haemato-Oncology 10th Anniversary of the Cochrane Haematological Malignancies

More information

Can I have FAITH in this Review?

Can I have FAITH in this Review? Can I have FAITH in this Review? Find Appraise Include Total Heterogeneity Paul Glasziou Centre for Research in Evidence Based Practice Bond University What do you do? For an acutely ill patient, you do

More information

Best of San Antonio Breast Cancer Symposium

Best of San Antonio Breast Cancer Symposium Best of San Antonio Breast Cancer Symposium 11:45 am - 5:00 pm 5800 Rockside Woods Blvd. About the Course The San Antonio Breast Cancer Symposium is an international meeting of laboratory and clinical

More information